Myelodysplastic Syndrome Clinical Trial

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

Summary

This phase II trial tests whether treosulfan, fludarabine, and rabbit antithymocyte globulin (rATG) work when given before a blood or bone marrow transplant (conditioning regimen) to cause fewer complications for patients with bone marrow failure diseases. Chemotherapy drugs, such as treosulfan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fludarabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. rATG is used to decrease the body's immune response and may improve bone marrow function and increase blood cell counts. Adding treosulfan to a conditioning regimen with fludarabine and rATG may result in patients having less severe complications after a blood or bone marrow transplant.

View Full Description

Full Description

OUTLINE:

CONDITIONING REGIMEN: Patients receive treosulfan intravenously (IV) over 120 minutes on days -6 to -4, fludarabine phosphate IV over 60 minutes on days -6 to -2, and lapine T-lymphocyte immune globulin (rATG) IV over 4-6 hours on days -4 to -2.

TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.

GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -2 and a taper beginning on day 180. Patients may also receive tacrolimus orally (PO). Patients also receive methotrexate IV on days 1, 3, 6, and 11.

After completion of study treatment, patients are followed up at 1 year from transplant.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient must be >= 1.0 year of age and less than 50.0 years of age at the time of enrollment (i.e. patient must have celebrated their 1st birthday when enrolled and must NOT have celebrated their 50th birthday when enrolled; 49.99 years)
Underlying BMFD treatable by allogenic HCT

Shwachman-Diamond syndrome

Criteria for Diagnosis:

A pathogenic mutation(s) for Shwachman-Diamond syndrome

For those patients tested but lacking a genetic mutation they must meet both **** criteria below:

Exocrine pancreatic dysfunction as defined by at least one of the following:

Pancreatic isoamylase below normal (age >= 3 years old), OR
Fecal elastase < 200, AND

Bone marrow failure as evidence by at least one of the following:

Intermittent or persistent neutropenia (absolute neutrophil count < 1,500/uL), OR
Hypo-productive anemia with a hemoglobin concentration below the age-related adjusted norms, OR
Unexplained macrocytosis, OR
Platelet count < 150,000/uL without alternative etiology, OR
Hypocellular bone marrow

Indications for HCT:

Severe neutropenia (absolute neutrophil count [ANC] < 500/uL), OR
Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia, OR
Severe thrombocytopenia (platelet count < 20,000/uL) or transfusion-dependent thrombocytopenia, OR
Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 eligibility review committee (ERC). In addition, patients with severe or recurrent infections will be reviewed by the ERC if they do not meet the indications for transplant listed above

Diamond Blackfan Anemia

Criteria for Diagnosis:

A pathogenic mutation for Diamond Blackfan anemia

For those patients tested but lacking a genetic mutation the patient must meet the first *** criteria and at least one of the subsequent *** criteria listed below:

History of deficiency of erythroid precursors in an otherwise cellular bone marrow AND,
Reticulocytopenia, OR
Elevated adenosine deaminase activity, OR
Elevated hemoglobin F, OR
Macrocytosis, OR
Congenital anomalies

Indications for HCT:

Red blood cell (RBC) transfusion dependent anemia despite an adequate trial of steroids; OR
Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC

Congenital Sideroblastic anemia

Criteria for Diagnosis:

A pathogenic mutation(s) for sideroblastic anemia

For those patients tested but lacking a genetic mutation:

Presence of ringed sideroblasts in the bone marrow excluding acquired causes of ringed sideroblasts such as lead poisoning & zinc toxicity

Indications for HCT:

Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia OR
Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC

GATA2 mutation with associated marrow failure

Criteria for Diagnosis:

** A pathogenic mutation(s) for GATA2

Indications for HCT:

Severe neutropenia (ANC < 500/uL), OR
Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia, OR
Severe thrombocytopenia (platelet count < 20,000/uL) or transfusion-dependent thrombocytopenia, OR
Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC. In addition, patients with severe or recurrent infections will be reviewed by the ERC if they do not meet indications for transplant listed above

SAMD9 or SAMD9L disorders

Criteria for Diagnosis:

** A pathogenic mutation(s) for SAMD9 or SAMD9L

Indications for HCT:

Severe neutropenia (ANC < 500/uL), OR
Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia, OR
Severe thrombocytopenia (platelet count < 20,000/uL) or transfusion-dependent thrombocytopenia, OR
Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC

Congenital amegakaryocytic thrombocytopenia

Criteria for Diagnosis:

A pathogenic mutation(s) for congenital amegakaryocytic thrombocytopenia.

For those patients tested but lacking a genetic mutation the patient must meet criteria below:

Thrombocytopenia early in life, AND
History of bone marrow demonstrating megakaryocyte hypoplasia

Indications for HCT:

Severe thrombocytopenia (platelet count < 20,000/uL) or transfusion-dependent thrombocytopenia, OR
Neutropenia defined as an ANC < 500/uL, OR
Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia, OR
Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC

Paroxysmal nocturnal hemoglobinuria

Criteria for Diagnosis:

Paroxysmal nocturnal hemoglobinuria (PNH) clone size in granulocytes >= 10%, AND
Complement mediated intravascular hemolysis with an elevated LDH (above institutional upper limits of normal)

Indications for HCT:

PNH with thrombosis despite adequate medical management, OR
PNH with intravascular hemolysis requiring transfusion support despite adequate medical management, OR
Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC. In addition, patients with PNH and cytopenias may be considered for the protocol eligibility following review by protocol 1904 ERC

An undefined BMFD: a patient with a BMFD for whom a genetic mutation responsible for their bone marrow failure phenotype has not been identified (excluding PNH) will be eligible for this clinical trial following approval by Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1904 ERC

* A BMFD with a known genetic mutation but not listed above will be eligible for this clinical trial following approval by BMT CTN 1904 ERC

Patient and/or legal guardian must sign informed consent prior to initiation of conditioning for BMT CTN 1904
Females and males of childbearing potential must agree to practice 2 effective methods of contraception at the same time or agree to abstinence

Note: The following patients MUST be reviewed by the BMT CTN 1904 ERC in order to determine if they are eligible for this trial:

All patients with Shwachman-Diamond syndrome, Diamond Blackfan anemia, congenital sideroblastic anemia, and congenital amegakaryocytic thrombocytopenia who have had genetic testing and lack a genetic mutation
All patients with an undefined BMFD: a patient with a BMFD for whom a genetic mutation responsible for their bone marrow failure phenotype has not been identified, excluding PNH
All patients with a BMFD and a known genetic mutation that is not listed above
All patients with GATA2 mutation and associated marrow failure
All patients with SAMD9 or SAMD9L disorders
There may be circumstances where a treating physician will consider a transplant for a patient with a BMFD who does not meet all the criteria listed under "indications for HCT". In these situations, treating physicians may submit their patient to the BMT CTN 1904 ERC for review in order to determine if the patient is eligible for this clinical trial based on additional clinical or laboratory information
Many patients with BMFD can have bone marrow evaluations that raise concern for possible myelodysplastic syndrome (MDS) including but not limited to dysplastic bone marrow evaluations or cytogenetic abnormalities. However, in patients BMFD these findings are not necessarily diagnostic or consistent with MDS. Therefore, given the complexities of diagnosing MDS in patients with BMFD, all patients with bone marrow evaluations concerning for possible MDS should be submitted to the ERC for review to confirm or exclude MDS. This is particularly important as we do not want to exclude potentially eligible patients due to an incorrect diagnosis of MDS
HLA-MATCHED RELATED DONOR: HLA-matched sibling: Must be a minimum HLA-6/6 matched to the recipient at HLA-A, -B (serologic typing) and DRB1 (high-resolution typing)
HLA-MATCHED RELATED DONOR: HLA-matched related (phenotypic match): Fully matched for HLA-A, -B, -C, -DRB1, and DQB1 by high-resolution typing.
HLA-MATCHED RELATED DONOR: If a genetic mutation is known for the patient, the HLA-matched related donor [either HLA-matched sibling or HLA-matched related (phenotypic match)] must be screened for the same genetic mutation if clinically appropriate and should be confirmed to not have the same genetic disease (this does not include patients with PNH). Consult the protocol team with questions
HLA-MATCHED RELATED DONOR: If a patient has an undefined BMFD (a patient with a BMFD for whom a genetic mutation responsible for their bone marrow failure phenotype has not been identified), the HLA-matched related donor [either HLA-matched sibling or HLA-matched related (phenotypic match)] must have an evaluation as directed by the treating physician to confirm that the donor does not have the same underlying disease. This will include a complete blood count (CBC) with differential and potentially a bone marrow evaluation or other studies as directed by the treating physician
UNRELATED DONOR: Fully matched for HLA-A, -B, -C, -DRB1, and DQB1 by high-resolution typing
UNRELATED DONOR: Mismatched for a single HLA-class 1 allele (HLA-A, -B, or -C) by high-resolution typing; OR

UNRELATED DONOR: Mismatched for a single HLA DQB1 allele or antigen by high-resolution typing

* Note: donor patient (DP) matching per institutional practice

DONOR SELECTION RECCOMENDATIONS: in the case where there are multiple donor options, donors should be selected based on the following priority numbered below:

Unaffected fully HLA-matched sibling
Unaffected fully phenotypically HLA-matched related donor
Fully HLA-matched unrelated donor
Unrelated donor with single allele or antigen level mismatch at DQB1
Unrelated donor with single allele level mismatch at class 1 (HLA-A, -B, or -C)

Exclusion Criteria:

Patients with idiopathic aplastic anemia, Fanconi anemia, dyskeratosis congenita, and congenital neutropenia
Patients with MDS as defined by the World Health Organization (WHO) or leukemia
Prior allogeneic HCT
Patient's weight =< 10.0 kg (actual body weight and adjusted body weight) at time of study enrollment
Lansky (patients < 16 years of age) or Karnofsky (patients >= 16 years of age) performance < 70%

Left ventricular ejection fraction < 50% by echocardiogram or multi-gated acquisition (MUGA) scan

* For patients unable to obtain a left ventricular ejection fraction, left ventricular shortening fraction of < 26%

Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected/adjusted for hemoglobin) < 50%, forced expiratory volume (FEV)1 < 50% predicted, and forced vital capacity (FVC) < 50% predicted
For patients unable to perform pulmonary function tests (PFTs) due to age or developmental delay: oxygen (O2) saturation < 92% on room air
On supplemental oxygen
Estimated creatinine clearance < 60 mL/minute/1.73m^2 (estimated per institutional practice)
Dialysis dependent
Conjugated bilirubin > 2 x ULN for age (upper limit of normal [ULN], unless attributable to Gilbert's syndrome)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 4 x ULN for age, or
Fulminant liver failure or cirrhosis

Iron overload - This exclusion criterion only applies to patients who are considered at risk for hepatic or cardiac iron overload. Therefore, not all patients enrolled on this protocol will undergo formal hepatic or cardiac iron assessment

For patients >= 18 years with a history of significant transfusions defined as >= 8 packed red blood cell transfusions per year for >= 1 year or have received >= 20 packed red blood cell transfusions (lifetime cumulative) will require formal hepatic and cardiac iron measurement. In addition, patients with a prior history of hepatic or cardiac iron overload will also require formal assessment for iron overload. Patients are excluded if:

Hepatic iron content >= 8 mg Fe/g dry weight by liver magnetic resonance imaging (MRI) using a validated methodology (such as T2 * MRI or ferriscan) or liver biopsy per institutional practice
Cardiac iron content < 25 msec by cardiac T2 * MRI

For patients < 18 years old with a history of significant transfusions defined as >= 8 packed red blood cell transfusions per year for >= 1 year or have received >= 20 packed red blood cell transfusions (lifetime cumulative) will require formal hepatic iron measurement. In addition, patients with a prior history of liver iron overload will also require formal assessment for iron overload. Patients are excluded if:

Hepatic iron content >= 8 mg Fe/g dry weight by liver MRI using a validated methodology (such as T2 * MRI or ferriscan) or liver biopsy per institutional practice
Uncontrolled bacterial infection within 1 week of study enrollment. Uncontrolled is defined as currently taking medication with no clinical improvement or progression on adequate medical treatment
Uncontrolled viral or fungal infection within 30 days of study enrollment. Uncontrolled is defined as currently taking medication with no clinical improvement or progression on adequate medical treatment
Positive for human immunodeficiency virus (HIV)
Presence of clinically significant anti-donor human leukocyte antigen (HLA)-antibodies per institutional practice
Prior solid organ transplant
Patients with prior malignancies except resected non-melanoma skin cancer or treated cervical carcinoma in situ
Demonstrated lack of compliance with prior medical care as determined by referring physician
Females who are pregnant or breast-feeding
Known hypersensitivity to treosulfan or fludarabine
Known life-threatening reaction (i.e. anaphylaxis) to Thymoglobulin that would prohibit use for the patient as this study requires use of the Thymoglobulin preparation of anti-thymocyte globulin (ATG)

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT04965597

Recruitment Status:

Recruiting

Sponsor:

Fred Hutchinson Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 23 Locations for this study

See Locations Near You

Children's Hospital Los Angeles
Los Angeles California, 90027, United States More Info
Kimberly Arieli
Contact
[email protected]
Paibel Aguayo-Hiraldo, MD
Principal Investigator
Rady Children's Hospital/UCSD
San Diego California, 92123, United States More Info
Mehrzad Milburn
Contact
[email protected]
Sheila Medina-Torne
Contact
[email protected]
Nicholas Gloude, MD
Principal Investigator
University of California San Francisco
San Francisco California, 94143, United States More Info
Kevin Magruder
Contact
[email protected]
Kristin Shimano, MD
Principal Investigator
Children's Hospital Colorado
Aurora Colorado, 80045, United States More Info
Courtney Newbold
Contact
[email protected]
Jessica Knight-Perry, MD
Principal Investigator
Children's Healthcare of Atlanta
Atlanta Georgia, 30329, United States More Info
Judson Russell
Contact
[email protected]
Kathryn Leung, MD
Principal Investigator
Johns Hopkins University
Baltimore Maryland, 21231, United States
Boston Children's Hospital
Boston Massachusetts, 02115, United States More Info
Brandi Bratrude
Contact
[email protected]
Leslie Lehmann, MD
Principal Investigator
University of Michigan Medical Center
Ann Arbor Michigan, 48109, United States More Info
Connie Varner
Contact
[email protected]
Mark Vander Lugt, MD
Principal Investigator
University of Minnesota
Minneapolis Minnesota, 55455, United States More Info
Merve Tekmen
Contact
[email protected]
Margaret MacMillan, MD
Principal Investigator
St. Louis Children's Hospital
Saint Louis Missouri, 63110, United States More Info
Lisa Murray
Contact
[email protected]
Shalini Shenoy, MD
Principal Investigator
Roswell Park Comprehensive Cancer Center
Buffalo New York, 14203, United States More Info
Rachel Carter
Contact
[email protected]
Barbara Bambach, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Kirsten Fuller
Contact
Maria Cancio, MD
Principal Investigator
Cohen Children's Hospital of NY
Queens New York, 11040, United States More Info
Amelia Halac
Contact
[email protected]
Jonathan Fish, MD
Principal Investigator
Duke University Medical Center
Durham North Carolina, 27705, United States More Info
Erin Arbuckle
Contact
[email protected]
Joanne Kurtzberg, MD
Principal Investigator
Cincinnati Children's Hospital
Cincinnati Ohio, 45229, United States More Info
Samantha (Sam) McBride
Contact
[email protected]
Kasiani Myers, MD
Principal Investigator
Nationwide Children's Hospital
Columbus Ohio, 43205, United States More Info
Lori Jewell
Contact
[email protected]
Rajinder Bajwa, MD
Principal Investigator
Oregon Health & Science University
Portland Oregon, 97239, United States More Info
Rebecca Hulme
Contact
[email protected]
Evan Shereck, MD
Principal Investigator
Children's Hospital of Philadelphia
Philadelphia Pennsylvania, 19104, United States More Info
Patricia Hankins
Contact
[email protected]
Timothy Olson, MD
Principal Investigator
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States More Info
Delia Darst
Contact
[email protected]
Jim Connelly, MD
Principal Investigator
MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
LaTarsha Williams
Contact
[email protected]
Kris Mahadeo, MD
Principal Investigator
Texas Children's Hospital
Houston Texas, 77030, United States More Info
Emily Jobe
Contact
[email protected]
Ghadir Sasa, MD
Principal Investigator
Primary Children's/University of Utah
Salt Lake City Utah, 84113, United States More Info
Rebecca Stoffel
Contact
[email protected]
Michael Pulsipher, MD
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Seattle Washington, 98109, United States More Info
Courtney Vandervlugt
Contact
[email protected]
Lauri Burroughs, MD
Principal Investigator
Medical College of Wisconsin/Children's Hospital of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Emily Ruskiewicz
Contact
[email protected]
Julie Talano, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT04965597

Recruitment Status:

Recruiting

Sponsor:


Fred Hutchinson Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.